Experienced in Undifferentiated Connective Tissue Disease (UCTD)

Dr. Dominick G. Sudano

Rheumatology
Catalina Pointe Arthritis And Rheumatology Specialists, PC
7520 N Oracle Rd, Suite 100, 
Tucson, AZ 
Offers Telehealth
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Catalina Pointe Arthritis And Rheumatology Specialists, PC
7520 N Oracle Rd, Suite 100, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dominick Sudano is a Rheumatologist in Tucson, Arizona. Dr. Sudano is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), Osteoporosis, and Postmenopausal Osteoporosis.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

CATALINA POINTE ARTHRITIS AND RHEUMATOLOGY SPECIALISTS, PC
7520 N Oracle Rd, Suite 100, Tucson, AZ 85704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

6 Total Publications

Coccidioides Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases.
Coccidioides Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases.
Journal: ACR open rheumatology
Published: August 31, 2023
Similar Doctors
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Shannon Howe
Rheumatology
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Shannon Howe
Rheumatology

Tmc Medical Network

2380 N Ferguson Ave, 
Tucson, AZ 
 (8.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shannon Howe is a Rheumatologist in Tucson, Arizona. Dr. Howe is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Temporal Arteritis, Giant Cell Arteritis (GCA), and Juvenile Temporal Arteritis. Dr. Howe is currently accepting new patients.

Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ernest R. Vina
Rheumatology
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ernest R. Vina
Rheumatology

Banner-University Medical Group

1625 N Campbell Ave, 
Tucson, AZ 
 (7.1 miles away)
520-694-0111
Languages Spoken:
English
See accepted insurances

Ernest Vina is a Rheumatologist in Tucson, Arizona. Dr. Vina is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Arthritis, Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Lupus Nephritis, and Knee Replacement.

Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Sabina R. Mian
Rheumatology
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Sabina R. Mian
Rheumatology

Tmc Medical Network

2840 E Skyline Dr, Suite 230, 
Tucson, AZ 
 (3.0 miles away)
520-324-1214
Languages Spoken:
English, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sabina Mian is a Rheumatologist in Tucson, Arizona. Dr. Mian is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Felty Syndrome, Systemic Sclerosis (SSc), and Scleroma. Dr. Mian is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sudano's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile